Answers are grounded in this paper and cite their sources.
Older patients with diffuse large B-cell lymphoma (DLBCL) have limited treatment options. Bispecific antibodies (BsAbs) are a novel immunotherapy with less acute toxicity compared to conventional therapies. This is a real-world analysis conducted to understand the safety and efficacy of BsAbs in older compared to younger patients. Adult patients with relapsed/refractory DLBCL who received commercially available BsAbs as a single agent between June 2023 and October 2025 across 10 U.S. centers in the CUBIC consortium were included. Key efficacy outcomes included response rates and survival; safety outcomes included cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The analysis included 256 patients stratified by 3 age groups: <65 (71 patients), 65-74 (81 patients), ≥75 (104 patients). Median prior lines of therapy was 3, 80% were refractory to most recent therapy, and 40% would have been considered pivotal trial ineligible. At median follow-up of 9 months, the 12-month progression-free survival (PFS) was 30% and 12-month overall survival (OS) was 45%. Grade ≥3 CRS occurred in 5% patients; ICANS grade ≥3 occurred in 2% patients. There was no statistically significant difference in outcomes between the 3 age cohorts <65, 65-74, ≥75 with 12-month PFS 21%, 26%, 38%; 12-month OS 35%, 42%, 49%; grade ≥3 CRS 6%, 5%, 4%; and grade ≥3 ICANS 3%, 2%, 1% respectively. On multivariable analysis, ECOG ≥2 and elevated LDH were associated with inferior PFS and OS. Our analysis demonstrates that BsAbs maintain comparable efficacy and safety across all age groups, including patients ≥75 years.
No takes yet. Share an insight, caveat, or question.
Thiruvengadam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: